General Surgical Innovations forms cardiovascular distribution deals:
This article was originally published in Clinica
General Surgical Innovations has signed exclusive distribution agreements for its range of cardiovascular products in the UK, Germany, Belgium, Holland, Italy, Portugal, Spain. The agreements with unnamed distributors include its Endosaph system for the minimally-invasive harvesting of the saphenous vein and the surgical balloon dissector for subfascial endoscopic perforator surgery. The company has a direct sales force in the US and sells in Japan through an exclusive distribution agreement.
You may also be interested in...
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
While the COVID-19 pandemic continued to dominate EU-wide medtech decisions in May, further analysis of the one-year delay to the EU’s new regulations revealed some unexpected consequences. Meanwhile, a new flurry of documents and decisions have been produced by the European Commission.